1d
Andrews McMeel Syndication on MSNAnimal Doctor: Concerns About Several Veterinary Drug ProductsPlease see the following from Dogs Naturally magazine:. "Thousands of pet owners experienced devastating and deadly effects Seresto flea collars. "Two pet owners filed this class-action lawsuit in ...
Republicans in the Iowa Senate advanced a bill Wednesday that would limit lawsuits by Iowans seeking compensation for ...
In a significant legal ruling, Bayer AG has been ordered by a Washington state jury to pay $100 million to four individuals who claim they suffered health issues due to exposure to polychlorinated ...
Although Bayer’s top-selling drug Xarelto lost market exclusivity in most geographies in 2024, the company still predicts it will see strong growth from the pharma business unit beginning in 2027.
Bayer AG was told by a jury to pay $100 million to four people at a Seattle-area school who said their exposure at the facility to toxic chemicals made by the company’s Monsanto unit caused ...
Bayer’s Monsanto unit stopped making toxic polychlorinated biphenyls (PCBs) a half century ago, but the legal fallout lingers even as many of the building materials made with the chemicals are ...
University of Connecticut finds that 46% of Connecticut waterway samples are contaminated with levels of imidacloprid—the most widely used neonicotinoid.
Bayer argues PCB levels were safe, blames school for ignoring warnings Previous trials resulted in over $1.5 billion in verdicts Jan 14 (Reuters) - A Washington jury on Tuesday ordered Bayer ...
Bayer AG’s Monsanto unit stopped making toxic PCBs a half century ago, but the legal fallout lingers even as many of the building materials made with the chemicals are no longer used in US homes ...
(Reuters) -A Washington jury on Tuesday ordered Bayer to pay $100 million to four people who say they were sickened by toxic chemicals known as PCBs at a Seattle-area school, but found the company ...
Bayer’s Parkinson’s disease cell therapy is moving into late-stage testing, with the upcoming trial set to be the first registrational phase 3 study for an investigational allogeneic cell ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results